Summary
This 8-K filing is an amendment to a previous report filed on May 2, 2023, concerning Abbott Laboratories' (ABT) Annual Meeting of Shareholders held on April 28, 2023. The primary purpose of this amendment is to correct a typographical error in the reported number of shares cast against Michael F. Roman, a key executive. The amendment clarifies the voting results for Mr. Roman, providing updated figures for votes cast for, against, abstentions, and broker non-votes. For investors, this filing is largely administrative and confirms the original outcome of the shareholder vote regarding Mr. Roman's re-election. While the correction itself is minor and does not alter the overall outcome of the shareholder vote, it demonstrates Abbott's commitment to accurate reporting. The overwhelming majority of votes were cast in favor of Mr. Roman, indicating continued shareholder confidence in leadership.
Key Highlights
- 1Amendment to a prior 8-K filing regarding the 2023 Annual Meeting of Shareholders.
- 2Corrects a typographical error in the number of shares voted against Michael F. Roman.
- 3Provides updated and accurate voting tallies for Michael F. Roman: 1,315,610,421 votes For, 25,575,883 votes Against, 2,597,363 Abstain, and 179,678,846 Broker Non-Votes.
- 4The correction does not change the overall outcome of the vote concerning Michael F. Roman.
- 5Demonstrates commitment to accurate corporate disclosures.
- 6Confirms continued shareholder support for the company's leadership.